detroit r&d产品代理
detroit r&d产品代理
Detroit R&D 的原始项目是开发简单且廉价的高血压试剂盒，用于测量血液、尿液和组织中的新型脂肪酸生物标志物，现已发展成为一家在以下领域拥有领先技术的公司：a) 高血压、中风、心血管疾病和糖尿病 (由最终用户的 60 多篇同行评审出版物验证），b) 前列腺癌、乳腺癌和肺癌生物标志物，c) 环境雌激素，如 BPA 和 BPS，d) COX-2 生物标志物，e) 细胞色素 P450 (CYPs)，f ) 氧化应激，g) 线粒体 DNA 损伤和拷贝数，h) 糖基化 c-myc、p53 和 NF-kB，i) 聚糖微阵列，j) 伤口愈合和 k) 无标记纳米技术。
Detroit研发已经建立了成功的记录 a) 通过直接销售和通过 24 个分销商向美国和全球研究人员销售产品，b) 18 个美国国立卫生研究院 (NIH) SBIR 第一和第二阶段（> 1000 万）奖励给开发高血压诊断、线粒体 DNA 损伤测定、癌症微阵列、前列腺癌的糖基化生物标志物、乳腺癌中的糖基化蛋白和循环核酸肺癌生物标志物以及 c) 8 项已发布和 6 项待批专利。
总而言之，Detroit研发部门拥有大幅增长的才能、洞察力和动力。我们欢迎合作和/或许可查询。
Detroit R&D, Inc. was founded in 1997 by Dr. Hyesook Kim as a company dedicated to building a relationship of trust with the research community by providing the highest quality products through leading-edge technology. Detroit R&D has been steadily establishing itself as a worldwide source for novel diagnostic and drug-screening products. The Detroit R&D laboratories and offices are located in the heart of a new redevelopment district in the city of Detroit, Michigan.
Detroit R&D with an original project to develop easy and inexpensive hypertension kits for measuring novel fatty acid biomarkers in blood, urine and tissue has evolved to a company with leading-edge technologies in the fields of a) hypertension, stroke, cardiovascular diseases and diabetes (verified by >60 peer-reviewed publications by end-users), b) prostate, breast and lung cancer biomarkers, c) environmental estrogens such as BPA and BPS, d) COX-2 biomarker , e) cytochromes P450 (CYPs), f) oxidative stress, g) mitochondrial DNA damage and copy number, h) glycosylated c-myc, p53 and NF-kB, i) glycan microarrays, j) wound healing and k) label-free nanotechnology.
Detroit R&D has established a track record of success with a) sales of products to US and worldwide researchers by direct sales and via 24 distributors, b) 18 National Institutes of Health (NIH) SBIR Phases I and II (>10 million) awards to develop hypertension diagnostics, mitochondrial DNA damage assay, cancer microarrays, glycosylated biomarkers for prostate cancer, glycosylated proteins in breast cancer and circulating nucleic acid-based lung cancer biomarkers and c) 8 issued and 6 pending patents.
IN SUMMARY, Detroit R&D has the talent, insight and drives to grow substantially. We welcome collaboration and/or licensing inquiries.
